Managers / Q4 2020 · view latest →
Gates Foundation
CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100
Summary
Gates Foundation reported $438M in U.S.-listed holdings across 5 positions for Q4 2020.
The portfolio is heavily concentrated: Curevac N V alone accounts for 58.0% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Other · 58.0% · $254M
- Common Stock · 22.6% · $99M
- ADR · 19.4% · $85M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CUREVAC N V | NEW | +3.13M | 3.13M | +$254M | $254M |
| BNTXBIONTECH SE | NEW | +1.04M | 1.04M | +$85M | $85M |
| VIRVIR BIOTECHNOLOGY INC | NEW | +2.78M | 2.78M | +$74M | $74M |
| ATRECA INC | NEW | +1.40M | 1.40M | +$23M | $23M |
| AMYRIS INC | NEW | +292.4K | 292.4K | +$2M | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | CUREVAC N V | COM | 58.02% | $254M | 3.13M |
| 2 | BNTXBIONTECH SEhistory → | SPONSORED ADS | 19.42% | $85M | 1.04M |
| 3 | VIRVIR BIOTECHNOLOGY INChistory → | COM | 16.90% | $74M | 2.78M |
| 4 | ATRECA INC | CL A COM | 5.25% | $23M | 1.40M |
| 5 | AMYRIS INC | COM NEW | 0.41% | $2M | 292.4K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $44M | 5 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $60M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $84M | 8 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $90M | 8 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $84M | 9 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $126M | 9 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $113M | 9 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $130M | 9 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 10 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $130M | 9 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 11 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $330M | 11 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $342M | 10 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $692M | 8 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $656M | 7 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $438M | 5 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.